Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Infectious disease R&D Pipeline

Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Programs 1,112

Quick answer

Infectious disease: NovaPharmaNews indexes 1,112 infectious disease clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Top sponsors

Pipeline programs

Page 11 of 24

  1. KLWS-V502-02

    BRIGHT MINDS BIOSCIENCES INC.

    Human Papilloma Virus Infection

    phase 2 mab completed

    1 trial

  2. LIK066

    Novartis Pharmaceuticals

    Obese Patients With Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  3. LP-98 20 mg

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV

    phase 2 small molecule active

    1 trial

  4. Late immunity following single immunization with GA2 sporozoites (GACHA)

    Disc Medicine

    Falciparum malaria

    phase 2 other active

    1 trial

  5. Lucinactant

    WINDTREE THERAPEUTICS INC /DE/

    COVID-19

    phase 2 small molecule completed

    1 trial

  6. Lumicitabine

    Janssen Cilag International NV

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    1 trial

  7. M19-965

    AbbVie Deutschland GmbH & Co. KG

    HIV infection

    phase 2 small molecule active

    1 trial

  8. MAU868

    Vera Therapeutics

    BK Virus Infection

    phase 2 small molecule completed

    1 trial

  9. MEDI8897

    MedImmune

    Respiratory Syncytial Virus Infections

    phase 2 small molecule completed

    1 trial

  10. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  11. MK-5592-127

    Merck Sharp and Dohme

    Fungal infection

    phase 2 small molecule active

    1 trial

  12. MK-6024-017

    Merck Sharp and Dohme

    Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  13. MK-8591-013

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

  14. MMV390048 40mg

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  15. MP-424 (Telaprevir)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  16. MRx-4DP0004

    4D Molecular Therapeutics

    COVID-19

    phase 2 small molecule terminated

    1 trial

  17. Maribavir

    Takeda

    Cytomegalovirus Infection

    phase 2 small molecule completed

    1 trial

  18. Mavrilimumab

    Kiniksa Pharmaceuticals International, plc

    COVID-19

    phase 2 small molecule completed

    3 trials

  19. Merimepodib

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  20. Meropenem-Vaborbactam

    Lacuna Pharma Pty Ltd

    Complicated Urinary Tract Infection (cUTI), Acute Pyelonephritis (AP)

    phase 2 small molecule active

    1 trial

  21. Metronidazole

    Teva Pharma GmbH

    Bacterial Vaginosis

    phase 2 small molecule completed

    1 trial

  22. Miricorilant

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    3 trials

  23. Miricorilant (Cohort A)

    CORCEPT THERAPEUTICS INC

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  24. Motavizumab, palivizumab

    MedImmune

    Respiratory Syncytial Virus Infections

    phase 2 mab completed

    1 trial

  25. Multimedia WORTH

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  26. NN9500-4656

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 2 small molecule active

    1 trial

  27. NOV-205

    Cellectar Biosciences

    Hepatitis C

    phase 2 small molecule completed

    2 trials

  28. NS2

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 2 small molecule completed

    1 trial

  29. Namodenoson

    Can-Fite BioPharma

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule active

    1 trial

  30. Namodenoson, Matching placebo for namodenoson

    Can-Fite BioPharma

    Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

    phase 2 small molecule active

    1 trial

  31. NestaCell®

    Vera Therapeutics

    COVID-19 Pneumonia

    phase 2 mab completed

    1 trial

  32. Norovirus Bivalent Vaccine

    Takeda

    Prevention From Norovirus Infection

    phase 2 mab completed

    1 trial

  33. ORMD-0801 QD

    ORAMED PHARMACEUTICALS INC.

    Nonalcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  34. OT-101

    Oncotelic Therapeutics

    COVID-19

    phase 2 small molecule active

    1 trial

  35. OZ439

    CNS Pharmaceuticals

    Malaria

    phase 2 small molecule completed

    1 trial

  36. Olorofim

    Biotech Pharmaceutical Co.,

    Invasive Fungal Infections

    phase 2 small molecule completed

    1 trial

  37. Opaganib

    RedHill Biopharma

    Coronavirus Infections

    phase 2 small molecule completed

    1 trial

  38. Oral Insulin

    ORAMED PHARMACEUTICALS INC.

    Non-Alcoholic Steatohepatitis (NASH)

    phase 2 mab completed

    1 trial

  39. Oral Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 small molecule completed

    1 trial

  40. PEG-IFNα

    Vir Biotechnology

    Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial

  41. PENNVAX-GP

    INOVIO PHARMACEUTICALS, INC.

    HIV-1-infection

    phase 2 mab completed

    1 trial

  42. PRO-nCOV-1002

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    2 trials

  43. PRO-nCOV-1003

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    1 trial

  44. PRO-nCOV-2002

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab on hold

    1 trial

  45. PRO-nCOV-2004

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab terminated

    1 trial

  46. PRO-nCOV-2009

    Sinovac Research and Development Co.,

    COVID-19

    phase 2 mab completed

    1 trial

  47. PUL-042 Inhalation Solution

    United Therapeutics Europe Ltd

    COVID-19

    phase 2 small molecule completed

    2 trials

  48. Part1:Recombinant two-component COVID-19 vaccine (CHO cell)

    Jian Li

    COVID-19

    phase 2 mab completed

    1 trial

Frequently asked questions

How many infectious disease pipeline programs are tracked?

1,112 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.